In 1991, the FDA approved the anti-depressant drug Zoloft for sale. Due to extensive marketing undertaken by Pfizer, the medication quickly became a popular option for those facing symptoms of depression. The company continues to market the drug to pregnant women, even though the medication has been linked to the potential for serious birth defects.

Zoloft Birth Defects Can Include:

These birth defects can cause long-term complications for infants and their families, with many of them persisting for the child’s entire life. Families may face frequent hospital trips to monitor a child’s health status, and the purchase and use of a range of medications and other medical treatments, which places both an emotional and financial burden on everyone.

Zoloft Birth Defects Litigation

There are currently several hundred cases pending against Pfizer for Zoloft related birth defects damages. These cases have been consolidated in a multi-district litigation (MDL) before the United States District Court for the Eastern District of Pennsylvania. Firm partner Ed Blizzard was appointed by the court to serve on the Plaintiffs’ Steering Committee for Zoloft Multi-District Litigation (MDL) 2342, In Re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation As one of the national leaders in the Zoloft birth defects litigation, Blizzard Law PLLC has unmatched experience prosecuting these claims. The number of cases is still expected to grow, and victims of Zoloft’s side effects may still be able to join the litigation.

If you or a loved one has suffered a birth defect due to the effects of Zoloft taken during a pregnancy, you could be eligible for compensation for your damages. The attorneys of Blizzard Law PLLC have experience pursuing complex pharmaceutical cases, and they can help you determine how your claim fits into existing litigation against Pfizer. You should not have to quietly shoulder the effects of a dangerous drug. We can guide you through the process of seeking compensation with as little stress as possible.